Excess sudden cardiac deaths after short-term clarithromycin administration in the CLARICOR trial: why is this so, and why are statins protective?

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Excess sudden cardiac deaths after short-term clarithromycin administration in the CLARICOR trial : why is this so, and why are statins protective? / Winkel, Per; Hilden, J; Hansen, Jørgen Fischer; Hildebrandt, Per; Kastrup, Jens; Kolmos, Hans Jørn; Kjøller, Erik; Jespersen, Christian M.; Gluud, Christian; Jensen, GB; CLARICOR Trial, Group.

In: Cardiology, Vol. 118, No. 1, 2011, p. 63-67.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Winkel, P, Hilden, J, Hansen, JF, Hildebrandt, P, Kastrup, J, Kolmos, HJ, Kjøller, E, Jespersen, CM, Gluud, C, Jensen, GB & CLARICOR Trial, G 2011, 'Excess sudden cardiac deaths after short-term clarithromycin administration in the CLARICOR trial: why is this so, and why are statins protective?', Cardiology, vol. 118, no. 1, pp. 63-67. https://doi.org/10.1159/000324533

APA

Winkel, P., Hilden, J., Hansen, J. F., Hildebrandt, P., Kastrup, J., Kolmos, H. J., Kjøller, E., Jespersen, C. M., Gluud, C., Jensen, GB., & CLARICOR Trial, G. (2011). Excess sudden cardiac deaths after short-term clarithromycin administration in the CLARICOR trial: why is this so, and why are statins protective? Cardiology, 118(1), 63-67. https://doi.org/10.1159/000324533

Vancouver

Winkel P, Hilden J, Hansen JF, Hildebrandt P, Kastrup J, Kolmos HJ et al. Excess sudden cardiac deaths after short-term clarithromycin administration in the CLARICOR trial: why is this so, and why are statins protective? Cardiology. 2011;118(1):63-67. https://doi.org/10.1159/000324533

Author

Winkel, Per ; Hilden, J ; Hansen, Jørgen Fischer ; Hildebrandt, Per ; Kastrup, Jens ; Kolmos, Hans Jørn ; Kjøller, Erik ; Jespersen, Christian M. ; Gluud, Christian ; Jensen, GB ; CLARICOR Trial, Group. / Excess sudden cardiac deaths after short-term clarithromycin administration in the CLARICOR trial : why is this so, and why are statins protective?. In: Cardiology. 2011 ; Vol. 118, No. 1. pp. 63-67.

Bibtex

@article{2fcb4dfe79ef4278bc8792d73d2bd7e5,
title = "Excess sudden cardiac deaths after short-term clarithromycin administration in the CLARICOR trial: why is this so, and why are statins protective?",
abstract = "Objectives: To elucidate potential mechanisms for the clarithromycin-induced excess mortality observed in the CLARICOR trial during 2.6 year follow-up of patients with stable coronary artery disease. Methods: Cox analyses using out-of-hospital death as a proxy for sudden death compared to in-hospital (nonsudden) death. Result: In 100 of 189 (53%) cardiovascular (CV) deaths in which it was possible to examine the question, there was a strong association between place of death and the classification of CV death as sudden or not-sudden. The excess mortality in the clarithromycin group was confined to sudden CV death in patients not on statins at trial entry (HR: 2.61, 95% CI: 1.69–4.05, p < 0.0005). Other categories of deaths showed no marked drug-placebo difference. Conclusions: Short-term clarithromycin administration was significantly associated with increased risk of sudden CV death in stable coronary heart disease patients not using statins. ",
author = "Per Winkel and J Hilden and Hansen, {J{\o}rgen Fischer} and Per Hildebrandt and Jens Kastrup and Kolmos, {Hans J{\o}rn} and Erik Kj{\o}ller and Jespersen, {Christian M.} and Christian Gluud and GB Jensen and {CLARICOR Trial}, Group",
year = "2011",
doi = "10.1159/000324533",
language = "English",
volume = "118",
pages = "63--67",
journal = "Cardiologia",
issn = "0008-6312",
publisher = "S Karger AG",
number = "1",

}

RIS

TY - JOUR

T1 - Excess sudden cardiac deaths after short-term clarithromycin administration in the CLARICOR trial

T2 - why is this so, and why are statins protective?

AU - Winkel, Per

AU - Hilden, J

AU - Hansen, Jørgen Fischer

AU - Hildebrandt, Per

AU - Kastrup, Jens

AU - Kolmos, Hans Jørn

AU - Kjøller, Erik

AU - Jespersen, Christian M.

AU - Gluud, Christian

AU - Jensen, GB

AU - CLARICOR Trial, Group

PY - 2011

Y1 - 2011

N2 - Objectives: To elucidate potential mechanisms for the clarithromycin-induced excess mortality observed in the CLARICOR trial during 2.6 year follow-up of patients with stable coronary artery disease. Methods: Cox analyses using out-of-hospital death as a proxy for sudden death compared to in-hospital (nonsudden) death. Result: In 100 of 189 (53%) cardiovascular (CV) deaths in which it was possible to examine the question, there was a strong association between place of death and the classification of CV death as sudden or not-sudden. The excess mortality in the clarithromycin group was confined to sudden CV death in patients not on statins at trial entry (HR: 2.61, 95% CI: 1.69–4.05, p < 0.0005). Other categories of deaths showed no marked drug-placebo difference. Conclusions: Short-term clarithromycin administration was significantly associated with increased risk of sudden CV death in stable coronary heart disease patients not using statins.

AB - Objectives: To elucidate potential mechanisms for the clarithromycin-induced excess mortality observed in the CLARICOR trial during 2.6 year follow-up of patients with stable coronary artery disease. Methods: Cox analyses using out-of-hospital death as a proxy for sudden death compared to in-hospital (nonsudden) death. Result: In 100 of 189 (53%) cardiovascular (CV) deaths in which it was possible to examine the question, there was a strong association between place of death and the classification of CV death as sudden or not-sudden. The excess mortality in the clarithromycin group was confined to sudden CV death in patients not on statins at trial entry (HR: 2.61, 95% CI: 1.69–4.05, p < 0.0005). Other categories of deaths showed no marked drug-placebo difference. Conclusions: Short-term clarithromycin administration was significantly associated with increased risk of sudden CV death in stable coronary heart disease patients not using statins.

U2 - 10.1159/000324533

DO - 10.1159/000324533

M3 - Journal article

VL - 118

SP - 63

EP - 67

JO - Cardiologia

JF - Cardiologia

SN - 0008-6312

IS - 1

ER -

ID: 33564437